TopoTarget PXD101-CLN-6 : Essai de phase 2 évaluant l’efficacité d’un traitement par belinostat chez des patients ayant un lymphome. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] A phase II clinical trial of PXD101 in patients with recurrent or refractory cutaneous and peripheral T-cell lymphomas.

• Country France
• organs Lymphomes non hodgkinien
• Specialty Thérapies Ciblées

A therapeutic and pharmacokinetic study of Savene (dexrazoxane) in the treatment of accidental anthracycline extravasation To examine pharmakokinetic parameter during the 3-day Savene treatment

• Country None
• organs None
• Specialty None

TOPO TARGET PTCL : Essai de phase 2 évaluant l'efficacité et la tolérance du bélinostat chez des patients ayant un lymphome périphérique à cellules T, réfractaire ou en rechute. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] A multicenter, open-label trial of belinostat in patients with relapsed or refractory peripheral T-cell lymphoma.

• Country France
• organs Lymphomes non hodgkinien
• Specialty Chimiothérapie

TopoTarget AP3003 : Essai de phase 2 évaluant l’efficacité et la tolérance d’un traitement par APO866 chez des patients ayant un mélanome. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] A multi-centre, two-stage, open label phase II study to assess the efficacy and safety of APO866 in the treatment of patients with advanced melanoma.

• Country France
• organs Mélanomes cutanés
• Specialty Thérapies Ciblées

Ensayo clínico en fase I-II de Topotect (dexrazoxano) y dosis altas de etopósido en el tratamiento de pacientes adultos con tumores cerebrales sólidos, primarios o secundarios Determinar la dosis máxima tolerada de Topotect (dexrazoxano) y etopósido en combinación, definiendo su perfil de seguridad y toxicidad. La toxicidad se evaluará a través de la variable principal 1 ...

• Country None
• organs None
• Specialty None

A Phase II Clinical Trial of PXD101 in Patients with Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas To determine the efficacy of PXD101 treatment as measured by objective response rate. Objective response (OR) is best overall response of CR or PR. CTCL response assessment is based on the severity-we...

• Country None
• organs None
• Specialty None

A randomised, double-blinded parallel group study to compare efficacy and tolerability of topically applied Baceca and Tazarotene against placebo and Tazarotene in patients with basal cell carcinoma The primary objective will be to determine the efficacy of repeated topical applications of Tazarotene together with Baceca or placebo in patients with basal cell carcinomas (BCC).

• Country None
• organs None
• Specialty None

A multicenter open label phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma To determine the anti-tumor activity of APO886 in patients with relapsed or refractory CTCL

• Country None
• organs None
• Specialty None

Apoxis AP3001 : Essai de phase 2 évaluant l’efficacité et la tolérance d’un traitement par APO866 chez des patients ayant un lymphome cutané à cellules T. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] L’objectif de l’essai est dévaluer l’efficacité et la tolérance d’un traitement par APO866 chez des patients ayant un lymphome. Les patients recevront une perfusion d’APO866 en continu (96 heures), t...

• Country France
• organs Lymphomes non hodgkinien
• Specialty Thérapies Ciblées

A phase II Clinical Trial of PXD101 in Patients with Advanced Multiple Myeloma • In patients with advanced myeloma to assess the efficacy of PXD101 treatment (as measured by response rate (CR, PR, MR, NC/SD, PD) using the response criteria of Bladé et al Br.J.Haematol. 1998, 102...

• Country None
• organs None
• Specialty None